Related references
Note: Only part of the references are listed.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia
Naveen Pemmaraju et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations
Sabine Kayser et al.
LEUKEMIA & LYMPHOMA (2014)
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Farhad Ravandi et al.
BLOOD (2013)
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD
Koichi Takahashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
Alfonso Quintas-Cardama et al.
BLOOD (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Therapeutic Advances in Acute Myeloid Leukemia
Alan Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy
Farhad Ravandi et al.
BLOOD (2010)
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
Pierre Fenaux et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse
Saiko Kurosawa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
William Blum et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Prognostic index for adult patients with acute myeloid leukemia in first relapse
DA Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Treatment of relapsed and refractory acute myelogenous leukemia
EH Estey
LEUKEMIA (2000)
Share Paper
